Natural killer cell receptors: New biology and insights into the graft-versus-leukemia effect

Sherif Farag, Todd A. Fehniger, Loredana Ruggeri, Andrea Velardi, Michael A. Caligiuri

Research output: Contribution to journalArticle

384 Citations (Scopus)

Abstract

Natural killer (NK) cells have held great promise for the immunotherapy of cancer for more than 3 decades. However, to date only modest clinical success has been achieved manipulating the NK cell compartment in patients with malignant disease. Progress in the field of NK cell receptors has revolutionized our concept of how NK cells selectively recognize and lyse tumor and virally infected cells while sparing normal cells. Major families of cell surface receptors that inhibit and activate NK cells to lyse target cells have been characterized, including killer cell immunoglobulinlike receptors (KIRs), C-type lectins, and natural cytotoxicity receptors (NCRs). Further, identification of NK receptor ligands and their expression on normal and transformed cells completes the information needed to begin development of rational clinical approaches to manipulating receptor/ligand interactions for clinical benefit. Indeed, clinical data suggest that mismatch of NK receptors and ligands during allogeneic bone marrow transplantation may be used to prevent leukemia relapse. Here, we review how NK cell receptors control natural cytotoxicity and novel approaches to manipulating NK receptor-ligand interactions for the potential benefit of patients with cancer.

Original languageEnglish (US)
Pages (from-to)1935-1947
Number of pages13
JournalBlood
Volume100
Issue number6
DOIs
StatePublished - Sep 15 2002
Externally publishedYes

Fingerprint

Natural Killer Cell Receptors
Grafts
Leukemia
Natural Killer Cells
Ligands
Transplants
Cytotoxicity
C-Type Lectins
Cell Surface Receptors
Neoplasms
Homologous Transplantation
Tumors
Bone
Bone Marrow Transplantation
Immunotherapy
Recurrence

ASJC Scopus subject areas

  • Hematology

Cite this

Natural killer cell receptors : New biology and insights into the graft-versus-leukemia effect. / Farag, Sherif; Fehniger, Todd A.; Ruggeri, Loredana; Velardi, Andrea; Caligiuri, Michael A.

In: Blood, Vol. 100, No. 6, 15.09.2002, p. 1935-1947.

Research output: Contribution to journalArticle

Farag, S, Fehniger, TA, Ruggeri, L, Velardi, A & Caligiuri, MA 2002, 'Natural killer cell receptors: New biology and insights into the graft-versus-leukemia effect', Blood, vol. 100, no. 6, pp. 1935-1947. https://doi.org/10.1182/blood-2002-02-0350
Farag, Sherif ; Fehniger, Todd A. ; Ruggeri, Loredana ; Velardi, Andrea ; Caligiuri, Michael A. / Natural killer cell receptors : New biology and insights into the graft-versus-leukemia effect. In: Blood. 2002 ; Vol. 100, No. 6. pp. 1935-1947.
@article{dce97ae0c4b241639851b5af4923db7d,
title = "Natural killer cell receptors: New biology and insights into the graft-versus-leukemia effect",
abstract = "Natural killer (NK) cells have held great promise for the immunotherapy of cancer for more than 3 decades. However, to date only modest clinical success has been achieved manipulating the NK cell compartment in patients with malignant disease. Progress in the field of NK cell receptors has revolutionized our concept of how NK cells selectively recognize and lyse tumor and virally infected cells while sparing normal cells. Major families of cell surface receptors that inhibit and activate NK cells to lyse target cells have been characterized, including killer cell immunoglobulinlike receptors (KIRs), C-type lectins, and natural cytotoxicity receptors (NCRs). Further, identification of NK receptor ligands and their expression on normal and transformed cells completes the information needed to begin development of rational clinical approaches to manipulating receptor/ligand interactions for clinical benefit. Indeed, clinical data suggest that mismatch of NK receptors and ligands during allogeneic bone marrow transplantation may be used to prevent leukemia relapse. Here, we review how NK cell receptors control natural cytotoxicity and novel approaches to manipulating NK receptor-ligand interactions for the potential benefit of patients with cancer.",
author = "Sherif Farag and Fehniger, {Todd A.} and Loredana Ruggeri and Andrea Velardi and Caligiuri, {Michael A.}",
year = "2002",
month = "9",
day = "15",
doi = "10.1182/blood-2002-02-0350",
language = "English (US)",
volume = "100",
pages = "1935--1947",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - Natural killer cell receptors

T2 - New biology and insights into the graft-versus-leukemia effect

AU - Farag, Sherif

AU - Fehniger, Todd A.

AU - Ruggeri, Loredana

AU - Velardi, Andrea

AU - Caligiuri, Michael A.

PY - 2002/9/15

Y1 - 2002/9/15

N2 - Natural killer (NK) cells have held great promise for the immunotherapy of cancer for more than 3 decades. However, to date only modest clinical success has been achieved manipulating the NK cell compartment in patients with malignant disease. Progress in the field of NK cell receptors has revolutionized our concept of how NK cells selectively recognize and lyse tumor and virally infected cells while sparing normal cells. Major families of cell surface receptors that inhibit and activate NK cells to lyse target cells have been characterized, including killer cell immunoglobulinlike receptors (KIRs), C-type lectins, and natural cytotoxicity receptors (NCRs). Further, identification of NK receptor ligands and their expression on normal and transformed cells completes the information needed to begin development of rational clinical approaches to manipulating receptor/ligand interactions for clinical benefit. Indeed, clinical data suggest that mismatch of NK receptors and ligands during allogeneic bone marrow transplantation may be used to prevent leukemia relapse. Here, we review how NK cell receptors control natural cytotoxicity and novel approaches to manipulating NK receptor-ligand interactions for the potential benefit of patients with cancer.

AB - Natural killer (NK) cells have held great promise for the immunotherapy of cancer for more than 3 decades. However, to date only modest clinical success has been achieved manipulating the NK cell compartment in patients with malignant disease. Progress in the field of NK cell receptors has revolutionized our concept of how NK cells selectively recognize and lyse tumor and virally infected cells while sparing normal cells. Major families of cell surface receptors that inhibit and activate NK cells to lyse target cells have been characterized, including killer cell immunoglobulinlike receptors (KIRs), C-type lectins, and natural cytotoxicity receptors (NCRs). Further, identification of NK receptor ligands and their expression on normal and transformed cells completes the information needed to begin development of rational clinical approaches to manipulating receptor/ligand interactions for clinical benefit. Indeed, clinical data suggest that mismatch of NK receptors and ligands during allogeneic bone marrow transplantation may be used to prevent leukemia relapse. Here, we review how NK cell receptors control natural cytotoxicity and novel approaches to manipulating NK receptor-ligand interactions for the potential benefit of patients with cancer.

UR - http://www.scopus.com/inward/record.url?scp=0037105453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037105453&partnerID=8YFLogxK

U2 - 10.1182/blood-2002-02-0350

DO - 10.1182/blood-2002-02-0350

M3 - Article

C2 - 12200350

AN - SCOPUS:0037105453

VL - 100

SP - 1935

EP - 1947

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -